Payment overview · 2025
General Payments
$611.13
25 reported records · 10 companies
Healthcare provider profile · identity verified
Ramon Leon, MD
Allopathic & Osteopathic Physicians|Family Medicine · MIAMI, FL · NPI 1073694337
Verified facts
What the public records show
CMS Open Payments records show Ramon Leon, MD received $611.13 in general payments during 2025 across 25 reported records.
PFIZER INC. accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $147.17 | 24.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $119.03 | 19.5% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $115.63 | 18.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $63.03 | 10.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.92 | 6.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.07 | 6.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.35 | 4.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.55 | 3.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.28 | 3.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.10 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $516.14 | 24 |
| Education | $94.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $98.56 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.32 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $55.32 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $42.80 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.92 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.92 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.07 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $28.35 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.21 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $26.21 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 114 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 221 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 124 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
221 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
124 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
114 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
37 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 460 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 325 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 279 | 99 |
| Losartan Potassium | Losartan Potassium | 252 | 80 |
| Alprazolam | Alprazolam | 235 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 222 | 73 |
| Mounjaro | Tirzepatide | 221 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 65 |
| Metformin Hcl | Metformin Hcl | 195 | 65 |
| Gabapentin | Gabapentin | 167 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 166 | 67 |
| Omeprazole | Omeprazole | 160 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 49 |
| Azithromycin | Azithromycin | 149 | 113 |
| Simvastatin | Simvastatin | 148 | 48 |
| Lisinopril | Lisinopril | 147 | 49 |
| Sertraline Hcl | Sertraline Hcl | 134 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 38 |
| Trazodone Hcl | Trazodone Hcl | 127 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 40 |
| Ozempic | Semaglutide | 124 | 28 |
| Meloxicam | Meloxicam | 121 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 39 |
| Eliquis | Apixaban | 114 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 114 | 38 |
| Montelukast Sodium | Montelukast Sodium | 111 | 36 |
| Clonazepam | Clonazepam | 100 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 27 |
| Memantine Hcl | Memantine Hcl | 99 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 33 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 97 | 48 |
| Allopurinol | Allopurinol | 86 | 25 |
| Famotidine | Famotidine | 85 | 34 |
| Tramadol Hcl | Tramadol Hcl | 82 | 28 |
| Atenolol | Atenolol | 81 | 23 |
| Temazepam | Temazepam | 79 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 27 |
| Farxiga | Dapagliflozin Propanediol | 76 | 21 |
| Furosemide | Furosemide | 75 | 25 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 69 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 34 |
| Methylprednisolone | Methylprednisolone | 67 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 43 |
| Ezetimibe | Ezetimibe | 57 | 19 |
| Sildenafil Citrate | Sildenafil Citrate | 57 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 43 |
| Synthroid | Levothyroxine Sodium | 55 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 54 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 54 | suppressed |
| Jardiance | Empagliflozin | 52 | 18 |
| Alendronate Sodium | Alendronate Sodium | 51 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 16 |
| Januvia | Sitagliptin Phosphate | 45 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 13 |
| Vascepa | Icosapent Ethyl | 44 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 23 |
| Ibuprofen | Ibuprofen | 40 | 17 |
| Donepezil Hcl | Donepezil Hcl | 39 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 11 |
| Metformin Hcl Er | Metformin Hcl | 39 | 13 |
| Mupirocin | Mupirocin | 38 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 20 |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 37 |
| Valsartan | Valsartan | 37 | 13 |
| Glimepiride | Glimepiride | 34 | 13 |
| Glipizide Er | Glipizide | 34 | 13 |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | 20 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | 11 |
| Carvedilol | Carvedilol | 31 | 12 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Prednisone | Prednisone | 26 | 11 |
| Tadalafil | Tadalafil | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 18 |
| Humalog Kwikpen U-200 | Insulin Lispro | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Colchicine | Colchicine | 19 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 18 |
| Folic Acid | Folic Acid | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $611.13 · 25 records | PFIZER INC. | AREXVY, ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, VYNDAMAX, VYNDAQEL, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error